Home › Research › Drug development
Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis
Hui EK, Mukadam N, Kohl G, Livingston G.. Journal of Alzheimer's disease : JAD, 2025-02-27
Topic: Risk, prevention and care in population studies
Plain-language summary
42 studies fulfilled inclusion criteria. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus placebo reduced dementia risk by 53% in three RCTs (n = 15,820, RR = 0.47[0.25, 0.86]) and 27% in three case-control studies (n = 312,856, RR = 0.73[0.54, 0.99], I 2 = 96%). Repaglinide was superior to glibenclamide by 0.8 points on the Mini-Mental State Examination scale in another RCT. Meta-analysis of seven longitudinal studies showed glitazones (n = 1,081,519, RR = 0.78[0.76, 0.81], I 2 = 0%) were associated with reduced dementia risk. Metformin (n = 999,349, RR = 0.94[0.79, 1.13], I 2 = 98.4%), sulfonylureas (RR = 0.98[0.78, 1.22], I 2 = 83.3%), dipeptidyl peptidase-IV inhibitors (DPP-1V) (n = 192,802, RR = 0.86[0.65, 1.15], I 2 = 92.9%) and insulin (n = 571,274, RR = 1.09[0.95, 1.25], I 2 = 94.8%) were not. Most studies were observational and limited by confounding by indication. In people with diabetes, RCTs consistently showed GLP-RAs reduce future dementia risk. Glitazones consistently showed protective effects, without heterogeneity, suggesting potential generalizability of these results. Metformin, sulfonylureas, insulin, and DPP-1V studies had inconsistent findings. If information is available future studies should consider dosage, severity, and duration.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hui, E. K., Mukadam, N., Kohl, G., & Livingston, G. (2025). Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis. Journal of Alzheimer's disease : JAD. https://doi.org/10.1177/13872877251319054
Vancouver
Hui EK, Mukadam N, Kohl G, Livingston G. Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis. Journal of Alzheimer's disease : JAD. 2025. doi:10.1177/13872877251319054. PMID: 40017057.
BibTeX
@article{hui2025-40017057,
author = {Hui, E. K. and Mukadam, N. and Kohl, G. and Livingston, G.},
title = {{Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2025},
doi = {10.1177/13872877251319054},
pmid = {40017057},
url = {https://doi.org/10.1177/13872877251319054}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus placebo reduced dementia risk by 53% in three RCTs (n = 15,820, RR = 0.47[0.25, 0.86]) and 27% in three case-control studies (n = 312,856, RR = 0.73[0.54, 0.99], I 2 = 96%).
- Repaglinide was superior to glibenclamide by 0.8 points on the Mini-Mental State Examination scale in another RCT.
- Meta-analysis of seven longitudinal studies showed glitazones (n = 1,081,519, RR = 0.78[0.76, 0.81], I 2 = 0%) were associated with reduced dementia risk.
- Metformin (n = 999,349, RR = 0.94[0.79, 1.13], I 2 = 98.4%), sulfonylureas (RR = 0.98[0.78, 1.22], I 2 = 83.3%), dipeptidyl peptidase-IV inhibitors (DPP-1V) (n = 192,802, RR = 0.86[0.65, 1.15], I 2 = 92.9%) and insulin (n = 571,274, RR = 1.09[0.95, 1.25], I 2 = 94.8%) were not.
- Most studies were observational and limited by confounding by indication.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Participants15,820
- Effect sizeRR = 0.47; RR = 0.73; RR = 0.78
- Evidence strengthHigh
How this study scored 90/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 52 of the 58 points we could judge it on, which is 90 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 15,820 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40017057) |
| Free to read | 2 / 2 | Free to read |
| Points | 52 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 52 of the 58 points we could judge it on is 90 out of 100. |
| Total | 90 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “diabetes”
5 studies in the library carry the topic tag “diabetes”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.